Goldman Sachs Adjusts Price Target on Bristol-Myers Squibb to $60 From $57

MT Newswires20:30 · Ratings

Bristol-Myers Squibb (BMY): Growth Potential Amid Strategic Acquisitions and Revenue Increase

Yahoo FinanceOct 19 03:26

Cantor Fitzgerald Reiterates Neutral on Bristol-Myers Squibb, Maintains $50 Price Target

BenzingaOct 18 19:56 · Ratings

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

BenzingaOct 18 02:32

Bristol-Myers Squibb Analyst Ratings

BenzingaOct 18 00:32 · Ratings

Bristol-Myers Squibb Company (BMY): A Bull Case Theory

Yahoo FinanceOct 17 22:48